Summary The EGF receptor is a transmembrane glycoprotein exerting mitogenic effects on epithelial cells. The purpose of the present study was to develop a sensitive enzyme-linked immunosorbent assay (ELISA) for determination of the epidermal growth factor receptor (EGFR) protein to examine whether the receptor was overexpressed in head and neck squamous cell carcinomas compared with the normal counterpart, and to establish whether clinicopathological correlations were present by investigating a broad spectrum of parameters (tumour size, clinical stage, positive lymph nodes, tumour site, histological grade, keratinisation, preoperative irradiation and clinical outcome). The assay employs two commercially available monoclonal antibodies, both detecting protein epitopes. The material comprises 60 head and neck carcinomas, corresponding normal tissue and normal oral mucosa from healthy individuals. The study demonstrates significantly higher receptor levels in tumours compared with normal tissue (P<0.002) and a range in tumours and normal tissues of 0.4-10.5 and 0.1 -4.3 nmol g-' membrane protein respectively. Quantitation of receptors in normal mucosa emphasises the importance of using the patients' corresponding normal tissue, because using the patients' mucosa resulted in 83% overexpression, while using normal mucosa (EGF) family. This is a rapidly growing family consisting of a number of structurally and/or functionally related membrane-anchored molecules (Massague and Pandiella, 1993) .
Transforming growth factor alpha (TGF-x), amphiregulin (AR), vaccinia virus growth factor (VVGF), heparin-binding EGF-like growth factor (HB-EGF) and betacellulin bind to the EGFR which is present on cells derived from all three germ layers, including the proliferative compartment of epithelia (De Larco and Todaro, 1978; Gusterson et al., 1984; Nanney et al., 1984; Stroobant et al., 1985; Shoyab et al., 1989; Higashiyama et al., 1991; Sasada et al., 1993) . The biological activities are initiated through a tyrosine kinase which is localised to the intracellular domain of EGFR (Chen et al., 1987) . Tyrosine kinase activity of the receptor is activated in clathrin-coated pits by ligand-induced dimerisation. Activated tyrosine kinase initiates a cascade of intracellular events, such as autophosphorylation of tyrosine residues, a rise in cytosolic calcium ions and pH and increased transcription of responsive genes such as c-fos, c-myc and c-ras, leading to pleotropic effects on cells including the stimulation of migration and mitogenesis (Barrandon and Green, 1987; Chen et al., 1987) .
EGFR is considered as a proto-oncogene product sharing sequence homology with oncogene and proto-oncogene products from v-erbB-1, c-erbB-2 (neu/HER-2), c-erbB-3 (HER-3) and c-erbB-4 (HER-4) (Downward et al., 1984; Schechter et al., 1985; Kraus et al., 1989; Plowman et al., 1993) . The highest degree of sequence identity is in the tyrosine kinase domain, which is essential for the biological effects of the EGFR (Chen et al., 1987) .
The importance of the EGFR system in proliferation is demonstrated using antibodies to EGFR achieving reversible Go growth arrest in normal epithelial cells (Stampfer et al., 1993) . Concerning tumour biology elevated expression of EGFRs has been found to be necessary for malignant transformation of NIH-3T3 cells in culture (Riedel et al., 1988; Di Marco et al., 1989) . In addition, in vivo experiments have shown that overexpression of EGFR is common in epidermoid malignancies and can be detected in human tumours (Ozanne et al., 1986; Nicholson et al., 1988; Yasui et al., 1988; Ozawa et al., 1989; Grimaux et al., 1990; van Dam et al., 1991) . Last but not least, amplification of the EGFR gene and/or overexpression of the gene product is correlated with a poor prognosis in breast cancer, oesophageal cancer and malignant gliomas (Nicholson et al., 1988; Ozawa et al., 1989; Grimaux et al., 1990; Hurtt et al., 1992) . These observations together suggest that elevated EGFR levels may play a role in either initiation or progression of malignancy.
In a recent study, using immunohistochemistry, we demonstrated the presence of EGFRs in 55 head and neck carcinomas (Christensen et al., 1992a,b) . A number of quantitative studies have demonstrated overexpression of EGFR in head and neck carcinomas (Ishitoya et al., 1989; Kawamoto et al., 1991; Santini et al., 1991; Scambia et al., 1991) . Some of these studies demonstrated a correlation with tumour size and clinical stage (Kawamoto et al., 1991; Santini et al., 1991) , others did not (Ishitoya et al., 1989; Scambia et al., 1991) .
The aim of the present study was to develop a sensitive two-site ELISA for quantitation of receptor proteins in head and neck carcinomas and to elucidate whether further clinicopathological correlations could be established with for example, histological grade, the effect of preoperative irradiation, nodal status, tumour location; and whether the overex-pression of the receptor protein could be an independent prognostic indicator for recurrence and/or patient survival.
Materials and methods

Patients
Fresh tissue samples were collected from 60 consecutive patients (Table I ) who underwent operations during 1990-93 in the Department of Oto-Laryngology -Head and Neck surgery, Rigshospitalet, University Hospital, Copenhagen. Most of the tumours were located in the oral cavity. Other locations included the nose and maxillary sinus. In 41 cases corresponding normal tissue was included. In addition, ten normal specimens of oral mucosa were obtained from healthy non-smokers (mean age 29 years; range 25-37 years) and ten from age-matched patients operated for non-cancer diseases (e.g. nose fracture or otitis media; mean age 62 years; range 48 -78 years). The project was approved by the regional Committee of Scientific Ethics, Copenhagen, and informed consent was obtained. Thirty-eight of the patients had received preoperative irradiation (62-68 Gy) ( Table I) . No patients had been treated with chemotherapeutic agents. All the patients were staged according to the UICC TNM classification (Spiessl et al., 1990) . At follow-up 30 patients suffered from recurrence.
The samples were obtained within 10-30min of surgery and frozen at -80°C. In order to ensure that the receptor protein was stable during this period, seven tumour specimens and corresponding normal tissues were divided into three pieces and frozen after 10, 20 and 30 min at room temperature.
In all cases verification of the tumour was made on frozen sections cut from the biopsies and stained with haematoxylin-eosin. Fifty-four of the tumours were squamous cell carcinomas, most of which were moderately differentiated (Table I ). In addition, the material included six malignant salivary gland tumours, three adenocarcinomas, two mucoepidermoid carcinomas and one clear cell carcinoma. The histological grade of the squamous cell carcinomas was determined on paraffin sections according to standard criteria (Kissane, 1990) . (Figures 2 and 3 ). Only seven of the biopsies demonstrated , fewer EGFRs in the tumour specimens than the normal epithelia (Figure 2) . The difference between tumour and normal tissue was significant with P <0.002 (paired ttest). No significant correlation was observed between the expression of EGFRs (expressed as absolute values or differences between tumour and normal tissue) and tumour size or clinical stage, although the mean differences were higher in samples from patients grouped as T2, T3, T4 and SII, SIII, SIV as compared with the values in samples obtained from patients grouped as TI and SI with P = 0.084 and 0.25 respectively. The clinicopathological data (i.e. histological grade, keratinisation of the squamous cell carcinomas, positive lymph nodes, anatomical locations of the tumours and the effect of preoperative irradiation), were analysed and no significant correlation with EGFR expression was found in tumour specimens (n = 53), or in normal tissue (n = 41), or with the difference between tumour and normal tissue (n = 41). The group of patients receiving preoperative irradiation (n = 38) was analysed separately concerning residual (n = 11) or recurring tumour (n = 28), however, no significant difference in EGFR level was seen.
Receptor expression in the tissue samples and the patients' Patients with malignant salivary gland carcinomas EGFRs measured in malignant salivary gland tumours demonstrated values similar to squamous cell carcinomas (P>0.1) (Figure 3 ) (mean 2.3; range 0.7-4.1 nmol g-' membrane protein). These tumours were derived from the minor salivary glands and, as corresponding normal tissue was not obtainable, overexpression could not be investigated.
Normal mucosa from patients and healthy individuals Analysis of receptor expression in normal tissue (n = 41) from patients with squamous cell carcinoma did not demonstrate a significantly higher level compared with healthy individual patients with non-cancer diseases (n = 20) (Figure 3) . However, in the subgroup consisting of younger healthy individuals (mean age 29 years), EGFR expression was significantly higher (mean 2.5; range 1.2 -3.4 nmol g-' membrane protein) compared with the patients' corresponding normal tissue (mean 1.7; range 0.1 -4.3 nmol g-' membrane protein) (P <0.03). In an age-matched group of individuals with non-cancer diseases (n = 10) the mean EGFR level was higher (mean 2. 1; range 1.7-3.1 nmol g-' membrane protein) compared with the mean value obtained from the patients' normal mucosa (mean 1.7; range 0.1 -4.3 nmol g-' membrane protein), but not significantly.
Patients' normal counterparts were also included in the analysis in order to evaluate if the EGFR level in surrounding non-diseased tissue reflected correlations with tumour size and/or clinical stage. However, no correlation could be determined. No significant difference in EGFR level was seen in normal epithelia between patients treated with primary surgery (n = 13) and patients receiving preoperative irradiation (n = 28) (P> 0.25). (Grimaux et al., 1990; In 1953 Slaughter et al published a classic report describSpyratos et al., 1994) . One reason for the differences could be ing the novel concept they called 'field cancerisation'. This the method used for receptor extraction. We have used a term referred to the basic pathogenic process that links the method that prevents the association of EGFR with the actin originally diagnosed tumours from head and neck cancer filaments and a relatively long incubation time (12 h) with patients with other primary tumours in the oropharynx, 2% triton X-100 (Hollenberg, 1990; (Figure 2 ) and may also EGFR mRNA in the group of patients suffering from cancer serve as an explanation for the tumour specimen expressing (Grandis and Tweardy, 1992 more likely mRNA stability and/or enhanced protease insensitivity (Eisbruch et al., 1987) . In accord with this hypothesis EGFR in A43 1, a cell line established from a vulva squamous cell carcinoma, appears to be degraded more slowly than in human fibroblasts (Wrann and Fox 1979, Krupp et al., 1982) , indicating enhanced protease insensitivity in malignant cells compared with normal cells.
Head and neck carcinomas have been investigated for other oncogene and proto-oncogene products besides EGFR (Merritt et al., 1990; Kearsley et al., 1991; Leonard et al., 1991) . The c-erbB-2 proto-oncogene product, which shares sequence homology with EGFR and which in breast cancer has been related to clinical outcome, has been found to be expressed in a very few to 50% of specimens from head and neck carcinomas and not related to clinical outcome (Schechter et al., 1985; Kearsley et al., 1991; Field et al., 1992) . One reason may be that this proto-oncogene product is expressed in particular in secretory cells and is therefore linked with adenocarcinomas (Gullick 1991) .
The importance of EGFR determination for head and neck cancer remains a contentious issue and currently it is not possible to evaluate this fully, but overexpression of this mitogenic receptor seems to be a general motif for these types of tumour and may contribute to the unregulated or abberrant proliferation observed in the malignant phenotype. It has not been possible to establish significant clinicopathological correlations at EGFR level. One reason may be methodological aspects as mentioned above, another that the EGFR system consists of both the receptor and a group of different ligands, which also have to be elucidated, before a final statement concerning the clinical relevance of this system can be confirmed.
